Company ProfilePremium

Joyzyme Group Limited

Company Profile Analysis

Ticker: 8622.HK愉悅集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Joyzyme Group Limited - Company showcase

Year Founded & Workforce

2017

98 Employees

Joyzyme Group Limited logo

Joyzyme Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Joyzyme Group Limited Overview

Joyzyme Group is a micro-cap Shenzhen-based medical device and health products company listed on Hong Kong's GEM board. Its legacy and still-dominant franchise is the research, manufacture and sale of in-vitro diagnostic (IVD) reagents for male infertility — a niche in which it holds a portfolio of 32 registered male fertility reagents — supplemented by parasite and Epstein-Barr virus antibody tests and auxiliary reproductive supplies. Revenue has been essentially flat at RMB24–28 million for eight years while losses have persisted every year since at least 2020. Following a change of control in October 2025 to enzyme-technology entrepreneur Dr. Zhou Xunyong, the group is repositioning toward women's health (via the June 2025 Keyue acquisition), Canadian-licensed nutraceuticals (Nutronic brand) and "silver economy" longevity products, under a new name evoking enzyme-based wellness. The investment case is now one of transition: a cash-rich, debt-light but shrinking-demand diagnostics business funding an unproven consumer health pivot.


Company's own description (AR2025 / IR2026)

In its notes to the financial statements, the group describes itself as principally engaged in the research and development, manufacturing, marketing and sale of (i) biological reagents and auxiliary reproductive supplies and equipment and (ii) healthcare products and supplements in the PRC. The AR2025 management discussion frames the biological reagents business as continued focus on male fertility IVD reagents, while the healthcare segment is presented as the vehicle for women's health, longevity and nutraceutical expansion. The co-chairman's statement in AR2025 positions the group's mission around the slogan "Fighting for fertility, building better beginnings" and describes a pivot from product supply toward an integrated healthcare service ecosystem.

Independent characterisation

Joyzyme is, in economic substance, two very different businesses held inside a cash shell:

  1. A mature, high-gross-margin specialty IVD reagent maker (≈78% of H1 2026 revenue) selling semen/seminal plasma biochemical and related reagents to PRC hospital andrology departments, reproductive medicine centres and distributors. Gross margins on this business are high (group margin was 67–68% before the healthcare segment diluted it), but scale is tiny (≈RMB25.5M p.a.) and the end-market is structurally pressured by China's collapsing birth rate (5.63‰ in 2025 versus 6.77‰ in 2024, cited in AR2025 from the National Bureau of Statistics).

  2. An early-stage consumer health business (≈22% of H1 2026 revenue) comprising Hunan Keyue Biotechnology (women's health supplements with a caregiver-service model, brands Yukunshu and Qinghuiyue) and the relaunched Canadian Nutronic brand (27 Health Canada Natural Health Product licences). This segment is loss-making at the segment-result level (−RMB0.99M in H1 2026) and carries a lower gross margin (≈45% in FY2025).

The group holds ≈RMB39M of cash and deposits against equity of ≈RMB49M (June 2026), so cash constitutes roughly 80% of book value; the operating businesses are being funded from this balance while new related-party and money-lender debt has been introduced.

Business and revenue model

DimensionCharacterisation
Revenue model mix~100% product sales (reagents, consumables, equipment, supplements). No subscription, licensing or recurring service revenue disclosed. Keyue's planned "caregiver service and experience" model is aspirational; no service revenue line is reported
Value chain positionUpstream manufacturer (reagents produced in Shenzhen); healthcare products appear to be a mix of own-brand and sourced/contract-manufactured goods (manufacturing arrangements not disclosed)
Customer typesHospitals, reproductive/andrology clinics and distributors for IVD (per prospectus framing and segment description); wholesale and e-commerce channels for healthcare products. One healthcare customer ("Customer A") contributed RMB2.27M (13.7% of group revenue) in H1 2026
Credit terms30–180 days for certain long-term customers; deposits required from others (IR2026 note 14)
End-marketsPRC male infertility diagnostics; PRC infectious disease serology (liver fluke/parasite, EBV); PRC assisted reproduction consumables; PRC women's health supplements; Canadian/North American natural health products (early)
Geography100% of revenue from the PRC (FY2025, H1 2026)

Strategy

Stated strategic themes (AR2025, IR2026)

Management's stated strategy can be summarised in five themes, paraphrased from the AR2025 co-chairman's statement and MD&A and the IR2026 outlook:

  1. Pivot from product supply to an integrated healthcare service ecosystem, explicitly framed around the "silver economy" and personalised healthcare.

  2. Women's health platform via Keyue, converting it into a "full-spectrum" service provider combining functional supplements, caregiver services and customer experience, expanded through offline business collaborations; flagship brands Yukunshu and Qinghuiyue. AR2025 targets "substantial growth in revenue in 2026".

  3. Nutronic brand strategy, using the East Asian "nominal age" (虛歲) concept to position preconception and pregnancy nutrition, leveraging 27 Health Canada licences.

  4. "Dual-engine" R&D across Canada and the PRC, pairing North American scientific credibility with PRC supply-chain efficiency, and expanding e-commerce and wholesale channels across North America, Southeast Asia and China to reduce single-market dependence.

  5. Sustain the legacy diagnostics technology base, especially chemiluminescence applications (sperm mitochondrial reagent, AMH).

Strategic initiatives (last 24 months)

DateInitiativeTypeStatus
Jul 2024Enzyme-based product trading via online platform and B2BNew businessAnnounced; separate results not reported
Aug–Oct 2024Appointment of enzyme and molecular pharmacology scientists as NEDsGovernance / capabilityBu Su remains; Xu Ming resigned Mar 2026
Apr–Jun 2025Keyue acquisition (91%)Diversification M&ACompleted; RMB3.6M revenue H1 2026
Oct–Dec 2025Change of control to Dr. Zhou XunyongOwnershipCompleted; 50.35%
Late 2025Three Class I chemiluminescence ancillary reagent registrationsProductRegistered
Jan–Feb 2026Rebrand to Joyzyme Group LimitedCorporate identityCompleted
Early 2026Nutronic relaunchNew brand≈RMB115k revenue H1 2026
H1 2026Sperm Morphology Analysis Assay Kit — Class II registrationProductH2 2026 launch planned
H1 2026Seminal plasma biochemical QC clinical researchR&DOngoing

ESG commitments

AR2025 references a commitment to "better births" advocacy, women's empowerment, reduced parenting stress and ethical governance across PRC, Hong Kong and Canadian operations. No quantified ESG targets were identified.

Cost programmes

None announced.

Medium-term financial targets / guidance

No quantified medium-term targets or formal guidance have been published. The only forward-looking financial statement is the qualitative aim of substantial revenue growth in 2026 from the Keyue platform.

Products & Services

Product-level disclosure in periodic reports is aggregated by category; individual SKU names, specifications and prices are not published in the retrieved filings. The catalogue below goes as granular as the public record allows.

Biological Reagents & Auxiliary Reproductive Supplies segment

Product lineDescriptionKey detailsTarget customerYear / statusPricing
Male fertility IVD reagents (32 products)Reagents for assessing semen and seminal plasma parameters in male infertility workupsCore franchise; RMB19.4M FY2025 (76.2% of segment); RMB10.4M H1 2026 (+4.4% YoY; 79.8% of segment). Count rose from 31 (end-2025) to 32 (mid-2026)Hospital andrology departments, reproductive medicine centres, distributorsOngoing—
Sperm Morphology Analysis Assay Kit (improved)Kit for morphological assessment of spermClass II medical device registration completed H1 2026; launch planned H2 2026As above2,026—
Chemiluminescence ancillary reagents (3 products)Ancillary reagents for chemiluminescence-based male fertility assessmentRegistered as Class I medical devices in late 2025As above2,025—
Sperm mitochondrial diagnostic reagent (pipeline)Chemiluminescence application for sperm mitochondrial functionDevelopment; referenced in AR2025 and IR2026 outlookAs abovePipeline—
Anti-Müllerian hormone (AMH) assay (pipeline/application)Chemiluminescence application of AMH for reproductive potential assessmentDevelopment; referenced in outlookFertility clinicsPipeline—
Seminal plasma biochemical QC (research)Clinical research for quality control of seminal plasma biochemical productsDrove +24.4% R&D spend in H1 2026Internal / regulatory2,026—
Parasite antibody detection reagents (2 products)Serological detection of parasite antibodies; includes liver fluke (Clonorchis) IVD reagentRMB3.9M FY2025; RMB1.40M H1 2026 (−3.9% YoY)Hospitals, CDC/infectious disease labs (endemic regions)Ongoing; liver fluke sales ≈RMB2.4M in FY2018—
Epstein-Barr virus antibody detection reagent (1 product)EBV serology (relevant to nasopharyngeal carcinoma screening in South China)≈RMB0.6M FY2025 (derived residual); RMB0.18M H1 2026 (−22.5% YoY)Hospitals, screening programmesOngoing—
Auxiliary reproductive supplies and equipmentConsumables and equipment for reproductive medicineRMB1.6M FY2025; RMB1.04M H1 2026 (+47.0% YoY)Reproductive centresOngoing—

Healthcare Products & Supplements segment

Product line / brandDescriptionKey detailsTarget customerYear / statusPricing
Keyue — Yukunshu (玉坤舒)Flagship women's health brandPositioned for physiological and recovery needs across female life cycleFemale consumers, PRCAcquired Jun 2025—
Keyue — Qinghuiyue (清徽悅)Flagship women's health brandAs aboveFemale consumers, PRCAcquired Jun 2025—
Keyue caregiver service model"Medical supplement product, caregivers' service and experience" model, expanded via business cooperationAspirational; no separate service revenue reportedFemale consumers2025–26—
NutronicCanadian natural health products brand; preconception/fertility nutrition messaging ("Loving you starting from a sperm") and longevity products27 valid Health Canada Natural Health Product licences; revenue ≈RMB115,000 in H1 2026Couples preparing for conception; ageing consumersRelaunched early 2026—
Longevity / "silver economy" functional foodsAnti-ageing and energy-support supplements for elderly and parentsStated development direction; no named productsElderly consumers, parentsPipeline—
Enzyme-based products (trading)Online/B2B trading of enzyme-based products announced Jul 2024Not reported as a separate revenue line; current status not disclosedConsumers/B2BAnnounced 2024—

Product revenue detail (half-year, IR2026 note 4)

Product revenue (CNY K)H1 2025H1 2026
Male fertility IVD reagents9,93310,371
Parasite antibody detection reagents1,4601,403
EBV antibody detection reagents231179
Auxiliary reproductive supplies and equipment7051,036
Healthcare products and supplements03,568
Total12,32916,557

Financial Narrative

Income statement

FY2021–23 EPS derived from net income ÷ weighted shares. FY2025 operating income derived (17.77 − 8.4 − 13.1 − 3.2 ≈ −6.93; excludes RMB1.2M trade receivable impairment). Dividends: no dividend recommended for FY2024 or FY2025 (AR2025); no dividend was identified for FY2021–FY2023.

Margins and growth

Revenue CAGR FY2021–FY2025: ≈2.0% (derived: 28.28 / 26.13 over four years). Excluding the acquired Keyue contribution, organic revenue CAGR is approximately −0.6%.

Cash flow

No buybacks occurred in H1 2026 (IR2026: no purchase, sale or redemption of listed securities).

Ratios

ROE FY2024 uses year-end equity; FY2025 uses average equity; H1 2026 annualises H1 loss on average equity. DSO = net trade receivables ÷ revenue × 365 (H1 annualised). Inventory and payable days, and therefore the full cash conversion cycle, are not computable with the data retrieved for prior years.

Commentary on trends, inflections and drivers

Revenue: eight years of stagnation, broken only by acquisition. Group revenue has oscillated in a RMB22–29M band since 2016 (aggregator history: FY2016 ≈25.4M, FY2018 ≈28.7M peak, FY2020 ≈22.0M COVID trough). The legacy reagent franchise grew just 0.7% in FY2025 and 5.4% in H1 2026. All of FY2025's 11.5% growth and most of H1 2026's 34.3% growth came from consolidating Keyue. On a like-for-like basis, the core business is flat in a market where births are falling sharply, which suggests share gains or price/mix offsets that management does not quantify.

Gross margin: high but now diluting. The reagent business sustains gross margins in the high 60s; group gross margin fell 4.5 points to 62.8% in FY2025 and to 63.8% in H1 2026 (from 68.3%) purely on mix, as healthcare products run at ≈45%. Further growth of the healthcare segment will mechanically compress group gross margin.

Operating costs: structurally too high for the revenue base. Operating expenses (selling, admin, R&D) of RMB24.7M in FY2025 exceed gross profit by ≈RMB7M. Administrative expense jumped 21.5% in FY2025 on professional fees for the Keyue acquisition and the mandatory general offer plus Keyue's own overheads. Selling expenses (≈30% of revenue) are high, consistent with a distributor- and hospital-detailing model. The group has not been profitable at the operating level in any year in the review period.

Below-the-line volatility. FY2025's reported loss was cushioned by a one-off ≈RMB2.6M gain from writing off an amount due to an associate (other income +374%) and a RMB0.22M impairment reversal; stripping these out, the underlying FY2025 loss was closer to RMB7.8M, the worst since FY2020. Trade receivable impairments rose more than twelve-fold to RMB1.2M in FY2025, which management attributes to weaker customer repayment capacity in the PRC.

Balance sheet: cash-rich but quality of receivables is a concern. Cash and deposits of RMB39–42M cover the market's entire non-cash book value several times over. However, the RMB6.1–6.3M credit loss allowance represents over a third of gross receivables, and more than a quarter of net receivables are aged over 181 days (RMB3.5M at June 2026). The group has introduced external debt for the first time — a HK$4M money-lender loan at 9% (FY2025, since extended 12 months) and HK$5M of 3% loans from the controlling shareholder (H1 2026) — despite holding ample cash, presumably reflecting the location of cash (largely in the PRC operating subsidiary) versus Hong Kong-level funding needs. Finance costs rose more than threefold in H1 2026.

Cash burn is accelerating. Operating cash outflow tripled to RMB4.8M in H1 2026. At this run-rate (≈RMB10M p.a. including capex), the cash pile provides roughly four years of runway absent a turnaround or new equity.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products/brands

Biological reagents and auxiliary reproductive supplies and equipment

Male fertility IVD reagents; parasite antibody detection reagents; EBV antibody detection reagent; auxiliary reproductive supplies and equipment

32 male fertility IVD reagents (mid-2026); Sperm Morphology Analysis Assay Kit (Class II); chemiluminescence ancillary reagents (Class I)

Healthcare products and supplements

Women's health supplements (Keyue); Canadian natural health products (Nutronic); enzyme-based products (status of 2024 trading initiative not separately reported)

Yukunshu (玉坤舒), Qinghuiyue (清徽悅), Nutronic

Segment revenue (CNY Mn)

Segment revenue (CNY Mn)FY2023FY2024FY2025

Biological reagents & auxiliary reproductive supplies

—25.425.5

Healthcare products & supplements

—02.8

Total group revenue

24.6325.3628.28

Segment Metrics FY2025 Details

Segment metrics FY2025 (AR2025)Value

Biological reagents segment YoY growth

+0.7% (+RMB173,000)

Healthcare segment revenue contribution

≈9.9% of group revenue (derived)

Healthcare segment gross margin

≈45.0%

Group gross margin

62.8% (FY2024: 67.3%)

Revenue by Segment and Segment Margins & Growth (%)

Segment (CNY K)H1 2025H1 2026

Biological reagents — revenue

12,32912,989

Biological reagents — segment result

5881,567

Healthcare products — revenue

03,568

Healthcare products — segment result

-545-993

Unallocated administrative expenses

-2,345-2,617

Loss before tax

-2,369-2,428

Derived H1 metrics

H1 2025

H1 2026

Biological reagents segment margin (%)

4.812.1

Healthcare segment margin (%)

—-27.8

Biological reagents share of revenue (%)

100.078.4

Healthcare share of revenue (%)

0.021.6

Group Entities

EntityRoleOwnership

Joyzyme Group Limited (Cayman)

Listed holding company

Anselme 50.35%; public float ≈49.65%

BVI intermediate holding companies

—100%

Shenzhen Huakang Bio-Medical Engineering Limited

Core IVD manufacturer; HNTE status

100% (indirect)

Hunan Keyue Biotechnology Company Limited

Women's health products

91% (indirect); 9% held directly by ED Zhang Yujing

Canadian operating entity (Nutronic)

Natural health products; holds Health Canada licences

Entity name and ownership not disclosed in retrieved filings

Associate (19% stake acquired 2023)

Anoectochilus extract IP

Carrying value nil at June 2026; amount due to associate written off in FY2025

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

26.1325.3324.6325.3628.28

Revenue growth YoY (%)

18.9-3.1-2.83.011.5

Gross profit (CNY Mn)

16.4616.9116.0917.0717.77

Selling & distribution expenses (CNY Mn)

———8.58.4

Administrative expenses (CNY Mn)

———10.813.1

R&D expenses (CNY Mn)

———2.83.2

Operating income (CNY Mn)

-4.58-5.09-7.39-5.01-6.93

EBITDA (CNY Mn)

-0.850.19-2.55-3.41—

Other income (CNY Mn)

———0.703.31

Pre-tax income (CNY Mn)

-3.90-3.01-5.78-4.16—

Net income attributable (CNY Mn)

-4.22-3.08-5.78-4.16-5.01

Weighted avg shares (M)

400.00404.64415.97482.48—

Basic EPS (MYR Bn cents)

-1.06-0.76-1.39-0.86-1.00

Diluted EPS (MYR Bn cents)

-1.06-0.76-1.39-0.86-1.00

Dividend per share (MYR Bn)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

63.066.865.367.362.8

Operating margin (%)

-17.5-20.1-30.0-19.8-24.5

EBITDA margin (%)

-3.30.7-10.4-13.4—

Net margin (%)

-16.2-12.2-23.5-16.4-17.7

R&D % of revenue

———11.011.3

Income Statement and Per-Share Data

Metric (CNY K)H1 2025H1 2026

Revenue

12,32916,557

Cost of sales

-3,913-5,993

Gross profit

8,41610,564

Other income

231121

Other losses (FX)

-147-289

Selling & distribution

-3,520-4,067

Administrative

-5,174-5,975

R&D

-1,839-2,288

Trade receivable impairment, net

-381-250

Reversal of loan/consideration impairment

1130

Finance costs

-68-244

Loss before tax

-2,369-2,428

Loss attributable to owners

-2,369-2,347

Basic & diluted LPS (MYR Bn cents)

-0.47-0.47

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2024FY2025

Total assets (CNY Mn)

———66.61

Cash, bank balances & >3-month deposits (CNY Mn)

——36.5041.94

Short-term borrowings (CNY Mn)

——03.60

Lease liabilities — current (CNY Mn)

———0.65

Lease liabilities — non-current (CNY Mn)

———0.70

Total debt incl. leases (CNY Mn)

——1.204.96

Net debt (negative = net cash) (CNY Mn)

——-35.30-36.98

Total equity (CNY Mn)

——54.0551.16

Goodwill (CNY Mn)

———0

Intangible assets (CNY Mn)

———0.78

Net current assets / working capital (CNY Mn)

———42.51

Gearing — debt incl. leases / equity (%)

——2.29.7

Balance sheet snapshot (CNY K)

31 Dec 2025

30 Jun 2026

——

Property, plant & equipment

7,2236,722——

Right-of-use assets

1,3432,272——

Intangible assets (capitalised development costs)

781509——

Inventories

3,2413,631——

Trade & bills receivables (net)

9,80711,932——

Gross trade & bills receivables

15,92618,212——

Credit loss allowance

6,1196,280——

Bank deposit > 3 months

5,0005,000——

Bank balances and cash

36,94034,242——

Total current assets

57,26256,719——

Total assets

66,60966,222——

Interest-bearing borrowings (money lender, 9%)

3,6043,604——

Borrowing from controlling shareholder (3%)

01,754——

Lease liabilities (total)

1,3532,305——

Total current liabilities

14,75416,365——

Net current assets

42,50840,354——

Total equity

51,15649,127——

Accumulated losses

-17,779-20,126——

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (CNY Mn)

00000

Share buybacks (CNY Mn)

00000

Cash flow (CNY K)

H1 2025

H1 2026

———

Net cash used in operating activities

-1,480-4,795———

Net cash from/(used in) investing activities

4,785-198———

Net cash from financing activities

1,5751,996———

PP&E purchases (capex)

404298———

Free cash flow (derived: OCF − capex)

-1,884-5,093———

Cash & equivalents, end of period

36,72534,242———

Margin Analysis (%) and Financial Ratios (x)

RatioFY2024FY2025H1 2026 (annualised where relevant)

ROE (%)

-7.7-9.5-9.7

ROA (%)

—-7.5-7.3

ROIC (%)

—

n/m (negative operating profit)

n/m

Current ratio (x)

—3.883.47

Debt incl. leases / equity (%)

2.29.715.6

Net debt / EBITDA (x)

n/m (net cash, negative EBITDA)

n/m

n/m

Interest coverage (x)

n/m

n/m (operating loss)

n/m

Asset turnover (x)

—0.420.50

DSO on net receivables (days)

—127131

Credit loss allowance / gross receivables (%)

—38.434.5

Region revenue (CNY Mn)

Region revenue (CNY Mn)FY2023FY2024FY2025

PRC

24.6325.3628.28

Hong Kong

000

Canada / North America

000

Other

000

Region revenue (CNY K)

H1 2025

H1 2026

—

PRC

12,32916,557—

Share Price History

DatePrice referenceContext

9 Apr 2020

0.125

Market price on option grant date

9 Oct 2025

0.126

Price paid by Anselme in private SPA

5 Dec 2025

0.395

Market price on option exercise date

9 Dec 2025

0.405

Market price on option exercise date

Recent (Oct 2026, timestamp unconfirmed)

0.380

ET Net real-time quote retrieved during research

Valuation Snapshot

MultipleValueBasis

Market capitalisation (HKD Mn)

196

515.472M shares × HK$0.38

P/E

n/m

Loss-making

P/B (x)

3.7

Equity RMB49.1M ≈ HK$53.6M (assumed HK$1.09/RMB)

EV (HKD Mn)

159

Market cap less net cash ≈ RMB33.8M (≈HK$36.8M) at 30 Jun 2026

EV/Sales TTM (x)

4.5

TTM revenue RMB32.5M (FY2025 − H1 2025 + H1 2026) ≈ HK$35.4M

EV/EBITDA

n/m

Negative EBITDA

Capital Markets

ItemStatus

Analyst coverage / consensus

None identified

Dividend history

No dividends declared in any period covered by this research; policy: discretionary based on results, capital needs and cash flow (AR2025)

Dividend policy

No fixed payout policy

Buyback authorisations

Standard general mandate customary for HK issuers; no repurchases executed in H1 2026

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

HK$4M money-lender loans (9%, maturity extended 12 months from original); HK$5M controlling-shareholder loans (3%, on demand); lease liabilities RMB1.6M current, RMB0.7M non-current (30 Jun 2026). No bank facilities

Equity issuance history

400M shares (2020–21) → 414.47M (Apr 2023) → 418.47M (Aug 2023) → 438.47M (Jan 2024 placing) → 500.47M (Apr 2024) → 515.47M (Dec 2025 option exercises)

Shares in issue (M, year end)

FY2021

Ordinary shares in issue

400.00

Analyst Conclusions

Management guidance

Management offers only qualitative guidance: cautious optimism amid soft PRC consumer demand and modest GDP growth; scale-up of healthcare products and supplements; overseas expansion (North America, Southeast Asia); e-commerce and wholesale diversification; continued chemiluminescence development; launch of the sperm morphology kit in H2 2026; and an aspiration for substantial revenue growth in 2026 from Keyue.

Consensus

No sell-side coverage or consensus estimates exist.

Bull case

  1. Legacy business has hidden earnings power. The reagent segment result nearly tripled to RMB1.57M in H1 2026 on 5% growth; if head-office costs normalise after one-off 2025 deal and offer fees, the group could approach break-even on an expanded revenue base.

  2. Cash cushion limits downside. ≈RMB39M cash and deposits against minimal external debt gives several years of runway and optionality for bolt-on deals.

  3. New controller brings capital and a thesis. Dr. Zhou's enzyme IP, consumer health network and willingness to fund at 3% could transform Joyzyme into a platform for his health businesses, with Keyue already annualising above RMB7M revenue.

Bear case

  1. No evidence of a profitable model. Losses in every year since at least 2020; underlying FY2025 loss (≈RMB7.8M ex one-offs) was the worst since the pandemic year, and operating cash burn tripled in H1 2026.

  2. Valuation detached from fundamentals. At ≈3.7x book and ≈4.5x EV/sales for a shrinking-market, loss-making micro-cap, the shares trade at roughly 3x the price the controller paid in October 2025.

  3. Governance and related-party complexity. Co-chair owns 9% of Keyue; the controller lends to the company; the board lost six directors in 15 months; disclosure inconsistencies appear in the latest interim report.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it mattersTiming
HNTE certificate renewal for Shenzhen HuakangPreserves 15% tax rate and signals R&D credentialsExpiry 14 Nov 2026
Sperm morphology kit commercial launchTest of new-product traction in core segmentH2 2026
FY2026 annual resultsWhether Keyue/Nutronic deliver "substantial" growth and whether losses narrow~Mar 2027
Operating cash flow trendRunway and potential need for equity raiseFY2026 results
Receivables ageing and impairmentsCustomer credit stressSemi-annual
Any asset injections or transactions with controller's other companiesPotential transformation and connected-transaction scrutinyUnscheduled
Equity fundraisingDilution risk given GEM historyUnscheduled
Board appointments (replacing Xu Ming)Governance stabilityUnscheduled
Money-lender loan maturity / refinancingLiquidity at HK levelExtended 12 months from original drawdown

Analyst verdict

Joyzyme Group is best understood not as a growing fertility-health company but as a small, cash-rich specialty diagnostics business in the early stages of a controller-driven transformation whose economics are unproven. The legacy male fertility reagent franchise is genuinely interesting: it carries high-60s gross margins, a broad registered portfolio, recent regulatory wins (Class I chemiluminescence reagents, a Class II sperm morphology kit), and showed clear operating leverage in H1 2026. Yet it has not grown organically in years, its end-market is shrinking as China's births fall, and its customers are paying more slowly — over a third of gross receivables are provisioned.

The diversification strategy layers a lower-margin, marketing-intensive consumer health business on top. Keyue was acquired for a token sum and is producing revenue, but the healthcare segment lost nearly RMB1M in the first half of 2026, and Nutronic's contribution is immaterial. Group-level cash burn tripled even as revenue rose by a third, and the company has begun borrowing at the holding level despite carrying ample PRC cash.

The October 2025 change of control is the pivotal event. Dr. Zhou acquired control at roughly HK$0.126 per share; the market now values the stock near HK$0.38, implying investors are paying for a transformation premium — presumably expectations of enzyme-based product synergies or future asset injections — for which no concrete plan, target or transaction has been disclosed. Governance signals are mixed: committees are properly constituted and the chair/CEO roles are separated, but related-party arrangements, rapid board turnover and minor disclosure errors warrant caution.

On the evidence available, the risk–reward is unfavourable for fundamentals-driven investors: the downside is cushioned by cash, but the valuation already embeds substantial success. Key evidence to change this view would be a narrowing of losses in FY2026, positive operating cash flow from the reagent segment, and transparent disclosure of any transactions with the controller's other businesses.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge (AR2025)Background and education

Dr. Zhou Xunyong (周訓勇)

Co-chairman, Executive Director; controlling shareholder

20 Nov 2025

50

Entrepreneur/researcher in enzyme-based theory for food, cosmetics, daily chemicals and tea; holds over 20 patents; author of a book on enzyme-based immune balance. BEng (Business Administration), Tianjin University (2002); Master of Laws, Fudan University (2011); DBA, Université Nice Sophia Antipolis (2016). Honorary chair, Vaccine and Immune Health Branch, Liaoning Immunology Society; committee member, national enzyme and fermentation engineering body. Director of Nasdaq-listed DT Cloud Star Acquisition Corp (from 26 Nov 2025) and Linkage Global Inc (from 13 Feb 2026), both resigned April 2026. Named a 2026 Forbes China industry pioneer innovator

Ms. Zhang Yujing (張玉靜)

Co-chairman, Executive Director; Nomination Committee chair; holds 9% of Keyue directly

16 Apr 2025 (chair from 29 Aug 2025; co-chair from 20 Nov 2025)

42

Healthcare industry experience; responsible for business operations and board management. Graduate of Hunan Women's University (2007)

Mr. Zhang Chunguang (張春光)

Executive Director and CEO

Joined group Jul 2008; director 3 Aug 2017

58

Over 10 years in PRC IVD reagents; Hubei Institute of Economics (economic English). Brother of former chairman Zhang Shuguang. Holds 3,976,000 shares (0.8%)

Mr. Poon Lai Yin Michael (潘禮賢)

Executive Director, CFO, Compliance Officer

3 Aug 2017

54

20+ years in audit, financial reporting and corporate finance (ex-Arthur Andersen). York University (BA), Monash (MPA), CityU HK (EMBA 2022), Tsinghua (MPA 2024); FCPA (HKICPA), CPA Australia. INED of LFG Investment (3938.HK) and Niche-Tech (8490.HK). Holds 4,000,000 shares (0.8%)

Dr. Bu Su (卜素)

Non-executive Director

8 Aug 2024

53

20+ years in molecular biomedicine and bioengineering; associate professor, Nanjing Forestry University (from 2014); former researcher at Amano Enzyme Inc. (Japan, 1998–2001); postdoctoral/research roles at University of Alabama at Birmingham; PhD Biochemistry, CUHK (2004)

Dr. Chow Kwok Fai Joseph (周國輝)

INED

16 Dec 2020

53

CEO of Zhejiang Thunderbio Innovation (molecular diagnostics, microfluidics) since 2018; BSc Monash; MMedSc and PhD, HKU

Mr. Tsui Wing Tak (徐永得)

INED; Audit Committee chair

22 Jan 2025

57

30+ years in accounting; FCPA (HKICPA), CPA (Australia); ED of KNT Holdings (1025.HK); INED of Bingo Group (8220.HK)

Ms. Wang Yachun (王亞純)

INED; Remuneration Committee chair

30 Jun 2025

42

Director of Jiangsu Zhengzhe Financial Management Consulting; BAcc, Hunan Agricultural University (2008); passed PRC CPA professional-stage exams (2014)

Executive Leadership Team

NameRoleJoinedAgeBackground

Mr. Chau Lai Ki (周麗麒)

Financial Controller and Company Secretary

25 Sep 2017

42

Practising member HKICPA; MPA PolyU; 20+ years finance

Mr. Fu Jianhua (傅劍華)

Deputy GM and CTO, Shenzhen Huakang

Jan 2014

60

BSc Wuhan University; 20+ years in medical devices and IVD

Board of Directors — Ms. Chow Ching Man

NameRoleDeparture dateContext

Ms. Chow Ching Man

INED

22 Jan 2025

Replaced by Tsui Wing Tak

Ms. Shih Mei Ling

INED

28 Feb 2025

Served under three months

Mr. He Jiaming

Executive Director

16 Apr 2025

Same day Zhang Yujing appointed and Keyue deal signed

Dr. Cheng Faat Ting Gary

INED

8 Jul 2025

Replaced by Wang Yachun

Mr. Zhang Shuguang

Chairman, Executive Director

29 Aug 2025

Founder exit; had sold controlling vehicle Crystal Grant in Jan 2025; 4,000,000 options cancelled

Dr. Xu Ming

Non-executive Director

30 Mar 2026

Reason not stated in retrieved filings

Directors' Remuneration

Director emoluments (CNY K)H1 2025H1 2026

Salaries, bonuses and other benefits

1,1671,281

Defined contribution plan contributions

119108

Total

1,2861,389

Directors' Remuneration by Attribute

AttributeStatus

Board size

8 (after Xu Ming's resignation 30 Mar 2026); 9 at AR2025 date

Composition

4 executive, 1 non-executive, 3 INEDs

Independence

3 of 8 = 37.5% (meets GEM one-third minimum)

Gender

3 female directors at AR2025 date (Zhang Yujing, Bu Su, Wang Yachun)

Chair/CEO separation

Yes — co-chairs (Zhou, Zhang Yujing); CEO Zhang Chunguang

Audit Committee

Tsui Wing Tak (chair), Chow Kwok Fai Joseph, Wang Yachun — all INEDs; 4 meetings in FY2025

Remuneration Committee

Wang Yachun (chair), Chow Kwok Fai Joseph, Zhang Chunguang (ED); 5 meetings in FY2025

Nomination Committee

Zhang Yujing (chair, ED), Chow Kwok Fai Joseph, Tsui Wing Tak, Wang Yachun; 6 meetings in FY2025

Board meetings FY2025

20 (plus 5 Independent Board Committee meetings related to the offer)

Major Shareholders

HolderShares%Note

Anselme Limited (Dr. Zhou Xunyong)

259,520,00050.35

Controlling shareholder

Poon Lai Yin Michael

4,000,0000.78

Director

Zhang Chunguang

3,976,0000.77

Director

Public float

≈247,976,000

≈48.1

Derived

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning relative to Joyzyme

Male fertility / andrology diagnostics (PRC)

Beijing Weili New Century Science & Technology (WLJY)

Domestic computer-assisted semen analysis (CASA) systems; instrument-led competitor in andrology labs

Male fertility / reproductive diagnostics (global)

Hamilton Thorne

Global CASA and ART laboratory equipment; premium segment

Chemiluminescence IVD (PRC)

Shenzhen New Industries Biomedical Engineering (Snibe)

Large-scale CLIA platform vendor; potential competitor for AMH/reproductive hormone assays

Chemiluminescence IVD (PRC)

Autobio Diagnostics

Large CLIA and microbiology IVD vendor

Chemiluminescence / broad IVD (PRC)

Mindray Medical

China's largest medical device group; CLIA immunoassay platforms

Broad IVD (PRC)

Maccura Biotechnology

Clinical chemistry and immunoassay reagents

Point-of-care / rapid tests (PRC)

Guangzhou Wondfo Biotech

Rapid tests including reproductive health; strong distribution

ART consumables (global)

Vitrolife Group

Global leader in IVF media and consumables

ART consumables (global)

CooperSurgical

Fertility consumables, devices and genomics

ART media (global)

FUJIFILM Irvine Scientific

IVF media and reagents

Women's health / supplements (PRC)

By-health (湯臣倍健)

China's leading VDS brand; massive scale versus Keyue

Women's / family nutrition (PRC/ANZ)

H&H Group (Swisse)

Premium supplements; strong cross-border e-commerce

Competitor Detail

MetricJoyzyme FY2025

Revenue (CNY Mn)

28.28

Revenue growth (%)

11.5

Gross margin (%)

62.8

Operating margin (%)

-24.5

R&D intensity (%)

11.3

Recent Developments

Not identified in the period: * layoffs, litigation, regulatory sanctions, guidance revisions, or contract wins with named customers.

Company Snapshot

$3.9M

Revenue

98

Employees

2017

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Net cash of ≈RMB37M at end-2025 (cash and deposits RMB41.9M vs debt incl. leases RMB5.0M), equivalent to ≈72% of total equity (AR2025).
  • High core gross margin: group gross margin of 67.3% in FY2024 before mix dilution; 68.3% in H1 2025 (AR2025, IR2026).
  • Broad niche portfolio: 35 registered biological reagents including 32 male fertility IVD reagents at June 2026 (IR2026).
  • Operating leverage in legacy segment: biological reagents segment result rose from RMB0.59M to RMB1.57M (H1 2025 to H1 2026) on 5.4% revenue growth (IR2026).
  • Regulatory assets: 27 Health Canada NHP licences (IR2026); new Class II registration for sperm morphology kit (H1 2026).
  • Tax efficiency: HNTE status gives Shenzhen Huakang a 15% EIT rate through 14 Nov 2026 (IR2026 note 8).
  • Committed controlling shareholder willing to lend at 3% (HK$5M loans in H1 2026), versus 9% from a money lender (IR2026).

Weaknesses

  • Chronic losses: net loss every year FY2020–FY2025 (−RMB11.6M, −4.2M, −3.1M, −5.8M, −4.2M, −5.0M) (TipRanks; AR2025).
  • Stagnant revenue: FY2021–FY2025 CAGR ≈2.0%, organic ≈−0.6% (derived).
  • Opex exceeds gross profit: FY2025 selling, admin and R&D of ≈RMB24.7M vs gross profit RMB17.8M (AR2025).
  • Receivable quality: credit loss allowance RMB6.3M = 34.5% of gross receivables; RMB3.5M aged over 181 days (IR2026 note 14).
  • Accelerating cash burn: H1 2026 operating cash outflow RMB4.8M vs RMB1.5M (IR2026).
  • Disclosure quality issues: inconsistent borrowing figure (RMB2.3M vs RMB3.6M) and LPS computation inconsistency in IR2026; no quantified targets.
  • Single-country revenue: 100% PRC (IR2026 note 4c).

Opportunities

  • Healthcare segment scale-up: Keyue revenue RMB3.6M in H1 2026 alone exceeds its FY2025 contribution (RMB2.8M for ~6 months) (IR2026, AR2025).
  • Chemiluminescence fertility assays (AMH, sperm mitochondrial function) could move the group toward higher-value testing (AR2025 outlook).
  • Sperm morphology kit launch in H2 2026 following Class II registration (IR2026).
  • Cross-border Nutronic leveraging Canadian licences into PRC and Southeast Asian e-commerce (IR2026).
  • Synergies with controlling shareholder's enzyme technology (20+ patents; enzyme-based consumer products) — not yet formalised (AR2025 biography).
  • PRC pro-natal policy could lift infertility diagnostics demand (contextual, AR2025).

Threats

  • Birth-rate collapse: PRC birth rate fell to 5.63‰ in 2025 from 6.77‰ (AR2025).
  • Customer credit deterioration: trade receivable impairment rose from RMB0.09M (FY2024) to RMB1.2M (FY2025) (AR2025).
  • HNTE renewal risk: certificate expires 14 Nov 2026; loss of status would raise statutory rate to 25% (relevant only once profitable) (IR2026).
  • Related-party / governance risk: Keyue 9% owned by co-chair; historic premises lease from former chairman's company; concentrated 50.35% control (AR2025, IR2026).
  • Platform competition: large CLIA vendors (Mindray, Snibe, Autobio) can incorporate reproductive assays into closed systems (industry context).
  • GEM market risk: HKEX's own GEM disclaimer highlights higher volatility and liquidity risk; dilution risk from further equity raises (issued shares +23% between 2023 and 2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Keyue 91% acquisition agreement signedFirst diversification move under new board influence
16 Apr 2025Zhang Yujing appointed ED; He Jiaming resignsBoard reshaping toward new owners' team
30 Apr 2025Further announcement on Keyue acquisitionDeal disclosure
26 Jun 2025Keyue acquisition completedHealthcare segment reactivated
30 Jun 2025Wang Yachun appointed INEDBoard refresh
8 Jul 2025INED Dr. Cheng Faat Ting Gary resignsBoard refresh
Aug 2025H1 2025 interim results: revenue RMB12.3M; loss RMB2.4MBaseline before change of control
29 Aug 2025Founder-chairman Zhang Shuguang resigns; Zhang Yujing becomes chairEnd of founder era
9 Oct 2025Anselme acquires 27.71% from Li King Yeung; MGO triggeredChange of control
28 Oct 2025Joint announcement on offerOffer process
20 Nov 2025Composite offer document; Dr. Zhou appointed co-chairmanNew controlling shareholder joins board
26 Nov 2025Dr. Zhou joins board of Nasdaq-listed DT Cloud Star Acquisition CorpController's outside commitments
5 & 9 Dec 202515M options exercisedDilution of ≈3%; insiders crystallise value at ≈3x the offer price
11 Dec 2025Offer closes at 50.35%Minimal acceptances; float preserved
15–23 Dec 2025Name change proposal announcementsRebrand initiated
Late 2025Three Class I chemiluminescence ancillary reagents registeredProduct pipeline
19 Jan 2026EGM approves name change; effective in CaymanRebrand
30 Jan 2026HK registration of new nameRebrand
9 Feb 2026Stock short name changes to JOYZYME GROUP; updated company information publishedMarket identity change
13 Feb 2026Dr. Zhou joins board of Nasdaq-listed Linkage Global IncController's outside commitments
Early 2026Nutronic brand relaunchedNew revenue stream
27 Mar 2026FY2025 results: revenue +11.5%; attributable loss RMB5.0M (+20.4%)Losses widen despite acquisition
30 Mar 2026NED Dr. Xu Ming resignsBoard shrinks to 8
Apr 2026Dr. Zhou resigns from both Nasdaq boardsFocus on Joyzyme
27 Apr 2026Annual Report 2025 publishedFull disclosure
H1 2026HK$5M loans from controlling shareholder at 3%Related-party funding
H1 2026Sperm Morphology Analysis Assay Kit Class II registrationProduct pipeline
28 Aug 2026H1 2026 interim results: revenue +34.3%; loss RMB2.4M; OCF −RMB4.8MGrowth via Keyue; burn accelerating

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit (FY2021–FY2025): Revenue rose from CNY 26.1 Mn in FY2021 to CNY 28.3 Mn in FY2025.
Joyzyme Group Limited — Income Statement: Revenue & Gross Profit (FY2021–FY2025)
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue26.125.324.625.428.3
Gross profit16.516.916.117.117.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.